CD274 and non-small cell lung carcinoma: In this study, we aimed to develop a radiomic signature to predict PD-L1 TPS ≥ 50% and to evaluate its potential ability to predict clinical outcomes in anti-PD-1 immunotherapy-treated metastatic NSCLC patients.